Results 41 to 50 of about 81,406 (283)

Revealing Cellular Heterogeneity and Key Regulatory Factors of Triple-Negative Breast Cancer through Single-Cell RNA Sequencing

Frontiers in Bioscience-Landmark
Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC). TNBC has a poor prognosis due to high intratumoral heterogeneity and metastasis, pointing to the need to explore distinct molecular subtypes and gene ...
Hu Zhang, Yanan Sun, Xinna Du
doaj   +1 more source

Cryptocaryone Exhibits ROS/MAPK-Dependent Antiproliferative and Apoptosis-Inducing Effects on Triple-Negative Breast Cancer Cells and Proof-of-Concept Breast Cancer Mouse Model. [PDF]

Drug Dev Res
ABSTRACT Omics’ technologies have enabled clinicians to gain previously unprecedented insights into the molecular complexity and clinical heterogeneity of triple‐negative breast cancer (TNBC). Increasingly it is being realized that TNBC does not respond well to current targeted therapies.
Chuang YT, Liu W, Chien TM, Farooqi AA, Chang HS, Shiau JP, Chang HW.   +6 more
europepmc   +2 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source

The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer in vivo

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Oestrogen related receptor α participated in the regulation of oxidative metabolism and mitochondrial biogenesis, and was overexpressed in many cancers including triple-negative breast cancer.
Zhipei Gao, Tianxiao Wang, Rui Li, Yongli Du, Han Lv, Liudi Zhang, Haifei Chen, Xiaojin Shi, Qunyi Li, Jingkang Shen   +9 more
doaj   +1 more source

Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages [PDF]

, 2018
Background: As crucial regulators of the immune response against pathogens, macrophages have been extensively shown also to be important players in several diseases, including cancer. Specifically, breast cancer macrophages tightly control the angiogenic
Blandino, Giovanni, Donzelli, Sara, Fazi, Francesco, Fontemaggi, Giulia, Gallo, Enzo, Iosue, Ilaria, Masciarelli, Silvia, Melucci, Elisa, Milano, Elisa, Mottolese, Marcella, Pruszko, Magdalena, Sacconi, Andrea, Terrenato, Irene, Zylicz, Alicja, Zylicz, Maciej   +14 more
core   +3 more sources

Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis [PDF]

Endocrine-Related Cancer, 2019
Triple-negative breast cancer (TNBC) accounts for ~20% of all breast cancer cases. The management of TNBC represents a challenge due to its aggressive phenotype, heterogeneity and lack of targeted therapy. Loss of cell differentiation and enrichment with breast cancer stem-like cells (BCSC) are features of TNBC contributing to its aggressive nature ...
Vanessa M, López-Ozuna, Ibrahim Y, Hachim, Mahmood Y, Hachim, Jean-Jacques, Lebrun, Suhad, Ali   +4 more
openaire   +2 more sources

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer

Molecular & Cellular Oncology, 2017
The proteasome machinery is a common target of gain-of-function p53 missense mutants. Upregulation of the proteasome fosters chemoresistance to proteasome inhibitors.
Kamil Lisek, Dawid Walerych, Giannino Del Sal   +2 more
doaj   +1 more source

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer [PDF]

, 2019
Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) is commonly observed in triple negative breast cancer (TNBC), leading to activation of the phosphoinositide 3-kinase (PI3K) signaling to promote tumor cell growth and chemotherapy ...
Guo, Zhanfang, Li, Shunqiang, Ma, Cynthia X, Rajput, Sandeep   +3 more
core   +1 more source